Evidence map›Paper›PMID 41473413›Full record

ReviewFrontiers in neuroscience2025

Established and emerging new approach methodologies in neuroscience.

Dorien Imberechts, Annelii Ny, Daniëlle Copmans

Abstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. New approach methodologies in neurotherapeutics development.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dorien ImberechtsLaboratory for Molecular Biodiscovery, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Annelii NyLaboratory for Molecular Biodiscovery, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Daniëlle CopmansLaboratory for Molecular Biodiscovery, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing need for ethical, human-relevant, and efficient alternatives to animal testing is driving the development of New Approach Methodologies (NAMs) in safety assessment and drug development. However, the inherent complexity of neurological diseases presents a significant challenge to fully replace animal models in this field. In neuroscience, a range of NAMs, from traditional 2D cell cultures to advanced brain organoids and alternative vertebrate models like zebrafish, demonstrate complementary strengths and limitations. Together, these models support translational research, including the investigation of neurodevelopment, disease, and neurotoxicity. While human and mouse brain organoids that mimic the structural and functional properties of mammalian brain tissue hold great promise, their applicability for high-throughput screening is hindered by their cost- and time-intensive nature. Complementary approaches such as embryonic and larval zebrafish models and the emerging zebrafish brain organoids provide faster, cost-effective, and scalable yet biologically relevant platforms for early-phase screening, thanks to the zebrafish's rapid development, conserved vertebrate neuroanatomy, and proven value in toxicology. This review maps the current landscape of NAMs in neuroscience, examining approaches ranging from 2D and 3D

Indexed as

brain organoidsdrug discoveryneurosciencesafety screeningzebrafish

Identifiers

PMID41473413
PMCPMC12745297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.